[{"Assets_0_Q2_USD":4544588000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-71550000.0,"NetIncomeLoss_1_Q2_USD":-17864000.0,"NetIncomeLoss_2_Q2_USD":-17864000.0,"StockholdersEquity_0_Q2_USD":494501000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":413787000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":688976000.0,"Ticker":"AMRX","CIK":"1723128","name":"AMNEAL PHARMACEUTICALS, INC.","OfficialName":"Amneal Pharmaceuticals Inc. Class A Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"632684518.0","Country":"nan","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20180809"}]